Combinatorial CRISPR screen identifies fitness effects of gene paralogues. by Thompson, Nicola A et al.
ARTICLE
Combinatorial CRISPR screen identifies fitness
effects of gene paralogues
Nicola A. Thompson1, Marco Ranzani1,5, Louise van der Weyden 1,5, Vivek Iyer1, Victoria Offord1,
Alastair Droop1, Fiona Behan 1, Emanuel Gonçalves 1, Anneliese Speak 1, Francesco Iorio 1,2,
James Hewinson1, Victoria Harle1, Holly Robertson1, Elizabeth Anderson1, Beiyuan Fu1, Fengtang Yang 1,
Guido Zagnoli-Vieira 3, Phil Chapman4, Martin Del Castillo Velasco-Herrera1, Mathew J. Garnett 1,
Stephen P. Jackson 3 & David J. Adams 1✉
Genetic redundancy has evolved as a way for human cells to survive the loss of genes that are
single copy and essential in other organisms, but also allows tumours to survive despite
having highly rearranged genomes. In this study we CRISPR screen 1191 gene pairs, including
paralogues and known and predicted synthetic lethal interactions to identify 105 gene
combinations whose co-disruption results in a loss of cellular fitness. 27 pairs influence
fitness across multiple cell lines including the paralogues FAM50A/FAM50B, two genes of
unknown function. Silencing of FAM50B occurs across a range of tumour types and in this
context disruption of FAM50A reduces cellular fitness whilst promoting micronucleus for-
mation and extensive perturbation of transcriptional programmes. Our studies reveal the
fitness effects of FAM50A/FAM50B in cancer cells.
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A major precept of cancer genetics is that normal cellsacquire somatic mutations that provide a fitness advan-tage and drive tumour evolution and growth. Since these
alterations are generally not found in normal cells, they may be
exploited therapeutically, either by direct pathway inhibition, for
example, in the context of activated oncogenes, or via synthetic
lethality. The concept of synthetic lethality was pioneered by the
yeast and Drosophila genetics communities who realised that the
disruption of multiple genes simultaneously could elicit cell death
in situations where disruption of such genes singly did not1. In
more recent times, synthetic lethality has been exploited as an
approach to treat cancers, the most notable example being the
development of PARP inhibitors to treat patients with BRCA1/2
mutant tumours2–4. Although substantial efforts have been made
to identify synthetic lethal (SL) interactions in human cancer
cells, we are still a significant way from having a genome-wide
map of cancer dependencies, with many established SL interac-
tions appearing to be highly context dependent5. Thus, systematic
screens for SL gene pairs represent a powerful approach to define
interactions that may be exploited in the clinic and to understand
the context dependencies in which they operate.
The mammalian genome has evolved to carry parallel path-
ways or in some cases multiple redundant genes on which cells
rely for survival—the principal reason for these gene sets seems to
be to buffer and protect cells from the adverse consequences of
gene loss, allowing cells to operate with higher fidelity and/or
plasticity, even under stressful conditions. One set of these genes
are the paralogues; genes derived from a common ancestral gene
that now reside in different regions of the genome6–9. As above,
several theories have been proposed for the creation of para-
logues, one being that paralogues have developed to create
functional redundancy, presumably as a result of selective pres-
sure. Examples of essential paralogues include RPL22L1 and
RPL22, which are ribosomal proteins, and YAP1/WWTR1(TAZ)
in the Hippo pathway9. Importantly, although several paralogue
dependencies have been established, we are currently unable to
accurately predict which paralogue pairs may be essential or
functionally related by their sequence alone. Intriguingly, many
essential paralogue pairs are part of the same protein complex8. A
good example of this are components of the BAF/PBAF com-
plexes, such as ARID1A/ARID1B and SMARCA2/SMARCA4,
which are required for a range of processes such as transcription
and chromatin regulation10,11. Disruption of these gene pairs
results in growth arrest and cell death; phenotypes which appear
to be influenced by cell lineage and differentiation status12.
As noted above, cancer cell line screens are powerful tools for
the identification of SL interactions because they can be used to
systematically and comprehensively screen the genome without
making any prior assumptions about which genes interact5,13.
Generally, these screens have been performed using either com-
pounds/targeted-agents, shRNA/siRNAs, or more recently with
CRISPR14–17. Many of these screens have been performed in the
context of specific genetic changes, such as in panels of cells with
defined genetic alterations, or in isogenic cell lines, so that genetic
interactions can be readily identified15,18. More recently, it has
become possible to use paired gRNAs, also known as combina-
torial or multiplex CRISPR screening, to identify essential gene
pairs19–24. This approach to exploring genetic epistasis facilitates
the identification of gene combinations that are SL by screening at
scale. Here, we deployed CRISPR screening to interrogate 1191
gene pairs including 645 paralogues, 447 mutually exclusive
genetic interactions defined using mutual exclusivity modelling of
cancer data, and a set of 95 literature curated SL pairs. Our
screening of two melanoma cell lines (A375 and MeWo) and a
retinal epithelial line (RPE-1) identified 27 SL pairs occurring in
≥2 cell lines. This included the poorly characterised Family with
sequence similarity 50 Member A & B (FAM50A/FAM50B) gene
pair, whose disruption precipitates a loss of cellular fitness asso-
ciated with apoptosis and widespread dysregulation of tran-
scription. FAM50A/FAM50B are particularly notable among our
collection of genetic interactions because ~4% of cancers profiled
by the TCGA show loss of FAM50B expression (0–10% across
tumour categories), thus highlighting the FAM50A/FAM50B axis
as a potential therapeutic target.
Results
Selection of gene pairs for combinatorial screening. Gene pair
sets were chosen to be included in our library based on three
distinct biological rationales (Fig. 1A). The first of these was a set
of putative SL partners derived from two published bioinformatic
analyses of human mutation and expression data25,26, where pairs
of genes had been identified as ‘co-lost’ less frequently than
expected by chance. We intersected the gene sets from these
studies, resulting in 447 overlapping candidate pairs for which
gRNAs could be designed. The second gene set consisted of the 95
highest scoring gene pair interactions for which gRNAs could be
designed as defined by a curated database of SL interactions
(SynLethDB)27. Notably, this set of genes includes pairs derived
from a vast array of biological contexts and tumour types, allowing
us to assess if these interactions were essential in our system and
in the cell lines we screened. Our library also included gRNAs for
four gene pairs to test interactions between PARG1/XRCC1,
KDM6A/UTY, KDM6A/KDM6B and KDM6B/UTY, implicated
from genome sequencing studies28. The final gene set consisted of
paralogous pairs. To define these genes, we built a computational
pipeline to identify paralogue pairs (two-member paralogue
families) with >20% DNA sequence homology/similarity and fil-
tered this collection to identify genes where there was a single
common orthologue in either Caenorhabditis elegans (Wormbase;
WS251) or Drosophila melanogaster (Flymine; FB2015_05) and
where disruption of this gene resulted in death of the organism. In
this way, we identified 701 gene pairs, 645 of which were amenable
to targeting by CRISPR (see Methods). In order to assess the
performance of our library we also included a panel of established
essential and non-essential genes29,30. A complete list of all gene
pairs is provided in Supplementary Data 1.
Library design, construction and cell line screening. Our library
was constructed using a dual promoter system (human U6 and
synthetic U6) and was assembled using Gibson cloning31. We
designed 3–5 guides for each gene and placed guides together as
pairs and also paired each of them with a non-targeting/control
guide, to allow assessment of both guide–guide and single-guide
activity (Fig. 1B; Supplementary Data 11–4 and Methods). Prior
to library construction, the efficiency of the paired gRNA con-
struct was confirmed by fluorescence-activated cell sorting
(FACS), utilising guides against two cell surface markers (CD15 &
CD33)32 (Supplementary Fig. 1 and Supplementary Data 2). We
used our library to screen two deeply characterised melanoma cell
lines (A375 and MeWo), and RPE-1 cells that are near-diploid
and non-transformed and thus represents a ‘normal’ comparator.
After lentiviral integration of Cas9, Cas9 activity (≥90%) of each
cell line was confirmed using a reporter assay32 (Supplementary
Fig. 2). Screens were performed in technical triplicate at 1000×
representation for a total of 28 days, harvesting cells for DNA
extraction and sequencing at day 14 and 28 (see Supplementary
Fig. 3 and Methods). Baseline values for gRNA abundance were
generated by infecting a non-Cas9-positive cell line in triplicate in
matched conditions to the dropout screen. These cells were
harvested at day 7.
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Benchmarking of screen performance. Before exploring our data
set for genetic interactions we elected to perform some bench-
marking analyses. To do this, we first used both MAGeCK33 and
BAGEL29 to compare the profile of gene essentiality by comparison
of the screen results to established essential and non-essential genes,
which were included in the library as controls (Supplementary Figs. 4
and 5). For all three cell lines, this analysis revealed a screen per-






























































































Fig. 1 Combinatorial CRISPR screen for cancer targets. A Schematic of the genes and gene pairs included in the paired gRNA library. The number of gene
pairs for which the minimum guide number could be identified with our gRNA selection criteria is shown. The number in brackets is the total number of pairs
in each category. B Design of the multiplex gRNA construct. To assess single-guide activity, a non-targeting gRNA (Fluc) was placed under the hU6 promoter
and the gRNA against the candidate gene was placed under the sU6 promoter. To assess paired gene activity, all five gRNAs for one gene were under the
hU6 promoter, whereas the guides targeting the other gene were under the sU6 promoter. C Derivation of residual values. The predicted log2-fold change
(FC) of the paired construct was calculated from the sum of the growth phenotypes of individual guides and the observed (experimentally determined)
log2FC was the actual behaviour of the pair in the screen. The behaviour of the population was modelled using Loess smoothing (blue line). The residual was
calculated as the vertical difference of any given point to the blue line. The more negative the residual, the more lethal the pair in the screen. The behaviour
of the gRNA pairs for the nine synthetic lethal interactions common to all cell lines is shown in the A375 cell line. D Overlap between the synthetic lethal
pairs identified in the screen in each of the three cell lines at Day 28. Significant gene pairs were defined as having a significantly more lethal pairwise effect
on cellular fitness than expected from the effect of each individual gene (see Methods). Pairs where one of the genes was found to be lethal in isolation at
Day 14 were excluded. E Percentage DNA sequence similarity between paralogues in our screen, identified as synthetic lethal in ≥1 cell line (Ever SL) vs zero
cell lines (Never SL). Error bars show mean and standard deviation (SD) with each data point representing the average sequence similarity between
paralogue pairs (see Source Data). The p value was determined using the two-tailed Mann–Whitney test.
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Analysis of combinatorial CRISPR screen data. The analysis to
identify interacting gene pairs was based on the Bliss model of
additivity35, whereby the effect of the gRNA pair was predicted
from the behaviour of each of the gRNAs by themselves (Fig. 1C).
Using this approach, we calculated both the expected and
observed lethality (fitness effect) of each gene pair and created a
population-based model (see Methods). In this way, for each given
gene pair, we were able to ascertain if the gene pair was sig-
nificantly more lethal, which in this context means more depleted
from the library transduced cell population, than expected by
comparing the lethality of the pair to the lethality associated with
individual gRNAs paired with a non-targeting/control gRNA.
Using this approach, we identified between 177 and 201 candidate
SL interactions per cell line, representing pairs of genes that sig-
nificantly impaired cellular fitness. Given the number of SL pairs
identified, we filtered the data to obtain a high-confidence set of
gene pairs. First, we observed that several of the pairs identified as
being potential candidate SL interactions contained a single gene
with a strongly negative growth phenotype. We reasoned that this
could be because some gRNAs were more efficient at disrupting
their target gene or that there were subtle imbalances in the
strength of the promoters used in the vector21. Thus, we filtered
from our hits any pairs containing a gene defined as essential in
either our screen (gRNA against a gene paired with a non-
targeting gRNA) at day 14 (to select genes whose loss resulted in a
cytotoxic rather than cytostatic effect), or an independent screen
performed on each respective cell line using a whole-genome
single gRNA CRISPR library34 (see Methods, Supplementary
Fig. 3). This approach refined our candidate list to 40–57 candi-
date SL interactions per cell line. Of the SL pairs identified in our
screen ~26% (27/105) were observed in two or more cell lines and
nine were found in all cell lines screened (Fig. 1D, Supplementary
Data 5).
SL is enriched between paralogous gene pairs. Among the hits
we identified, paralogues were highly over-represented (72/105
interactions, p= 0.002 two-tailed Fisher exact test), and all of the
nine interactions common to all three cell lines were paralogues
(Fig. 1D). Paralogues identified as SL gene pairs had a higher
pairwise DNA sequence similarity than non-SL paralogues
(p < 0.0001 (two-tailed Mann–Whitney test); Fig. 1E and Source
Data), most likely because as homology decreases, redundancy
between pair members also decreases. SL paralogues also had a
higher DNA sequence similarity than non-lethal paralogues when
compared with orthologues in simpler organisms (C. elegans/D.
melanogaster) (Supplementary Fig. 6 and Source Data).
Validation of SL pairs. We took eight individual gene pairs
identified as SL (five pairs identified as SL in 3/3 cell lines, two
pairs in 2/3 cell lines, one pair in 1/3 cell line), selected based on
their recurrence or biological interest, and proceeded to validate
these pairs using competitive cell growth assays. To do this, we
placed a gRNA targeting one of the genes in the pair in a
mCherry-expressing vector, and another, targeting the other gene,
in a BFP-expressing vector (see Methods). We transduced cells
with both vectors to create four populations (see below), and
measured population dynamics at timepoints between day 4 and
14 (Fig. 2A–B). These populations were either red or blue
fluorescent, where a single gRNA had been transduced,
untransduced cells with no fluorescence, or blue/red where both
gRNAs had been introduced. For each cell line (A375, RPE-1, and
MeWo) we established a baseline between non-interacting gene
pairs by selecting two non-essential genes (ACCSL/AIPL1)29 and
calculated the residual, representing a baseline neutral genetic
interaction in each cell line (see Methods, Supplementary Fig. 7).
We next compared the residual of each candidate SL gene pair to
that of the non-interacting pair, additionally including two extra
‘non-interacting pairs’ as negative controls. The concordance rate
between our validation experiments and the screen output was
95% (8/8 interactions in two cell lines, 7/8 in one cell line)
(Fig. 2C and Source Data). Supplementary Fig. 8 and Source Data
shows the fitness effects of disrupting each gene in the pair and
the predicted and observed lethalities as waterfall plots.
Comparison of the screen results to other data sets. Across the
cell lines screened in this study we identified a rich collection of SL
interactions, several of which were validated as described above.
To extend this analysis we compared our data to other previously
generated SL data sets (Supplementary Fig. 9 and Supplementary
Data 7). Specifically, we first looked for an overlap with the SL
interactions computationally predicted by De Kegel et al.8,
revealing 167/234 overlapping gene pairs were in agreement with
22 of these pairs ‘hits’ in both studies. These pairs included EAF1/
EAF2, DDX39A/DDX39B and CHMP1A/CHMP1B. In the same
way, we compared our data set to a study by Gonatopoulos-
Pournatzis et al.22 Noting that RPE-1 was the only cell line
screened in both studies, 94/170 overlapping genes pairs were
concordant as either hits or non-hits. Of these, 17 were defined as
SL interactions in both studies. These interactions included
CNOT7/CNOT8, TTC7A/TTC7B and SAR1A/SAR1B, all of which
are paralogous gene pairs. The gene pairs ARID1A/ARID1B,
SEC23A/SEC23B, SLC25A28/SLC25A37, SMARCA2/SMARCA4,
TTC7A/TTC7B and UAP1/UAP1L1 were hits in all three data sets.
Collectively, this analysis orthogonally validates nearly 40 SL
interactions and also the quality of our screen.
Identifying potentially therapeutically relevant genetic inter-
actions. We assessed the gene pairs identified as SL by our screen
for their cancer-translational potential using TCGA expression
data36. First, we searched for pairs where one member was not
expressed in a tumour type reasoning that disruption of the other
member of the pair may result in reduced tumour cell fitness.
Interestingly, we observed FAM50B expression to be lost in
tumours across a wide range of histological types including
melanoma, bladder and colon cancer whereas it was ubiquitously
expressed in normal tissue (Fig. 3A). Specifically, 355/9263 (4%)
of tumours have a TPM < 1 (range 0–10% across tumour cate-
gories) (Supplementary Data 6). Of note, FAM50B is an
imprinted gene with a paternal expression pattern, rendering it
susceptible to copy number events and loss of heterozygosity37,38.
Analysis of genome-wide methylome data revealed FAM50B
promoter methylation in cell lines that had lost expression of the
gene (Supplementary Fig. 10). Collectively, these data suggest that
a proportion of human cancers could be selectively targeted by
disruption or suppression of FAM50A.
Fitness effect of the FAM50A/FAM50B genetic interaction. We
first sought to validate the FAM50A/FAM50B genetic interaction
computationally using an independent data set34. Referencing
whole-genome CRISPR screening data against cell line expression
data suggested a significant dependency on FAM50A in cell lines
with low or no FAM50B expression (TPM < 1; p < 2.2 × 10−16,
Mann–Whitney–Wilcoxon Test) (Fig. 3B, Supplementary Data 8).
We next generated isogenic knockout or isogenic “rescued” cell
lines for in vitro experiments. First, using the A375 cell line, which
constitutively expresses both FAM50A and FAM50B, we created a
FAM50B knockout clone using CRISPR-Cas9 (Supplementary
Fig. 11). Consequently, through use of a competitive growth assay,
we found a dependency of this line on FAM50A (Fig. 3C and
Source Data). We next took two cell lines (RKO [colorectal] and
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TOV21G [ovarian]) where FAM50B was methylated and not
expressed and used lentiviral transduction to introduce a FAM50B
cDNA construct, showing that FAM50B expression (F50B+)
rescued the lethal phenotype associated with FAM50A disruption
(Fig. 3C). To further assess this relationship, we performed clo-
nogenic survival assays (Fig. 3D and Supplementary Fig. 12) in
RKO cells engineered to carry a doxycycline (Dox)-inducible
FAM50A gRNA further validating the FAM50A/FAM50B inter-
action. Thus, we have validated the genetic interaction between
FAM50A/FAM50B using an orthogonal data set, by using isogenic
FAM50B knockout cells, cell lines that had lost FAM50B expres-
sion during their evolution, and also by genetic rescue in a range
of cell line models.
Of note, in our CRISPR screens we observed that inactivation
of FAM50A alone (Supplementary Fig. 8 and Supplementary
Data 1) was associated with an apparent loss of cellular fitness,
despite the fact that we could readily derive FAM50A knockout
clones (Supplementary Fig. 11). As a therapeutic target this might
suggest that inhibition of FAM50A could have limiting toxicity. In
this regard, we recently reported a new developmental syndrome
(Armfield syndrome) associated with germline hypomorphic
alleles of FAM50A where patients developed to adulthood with
phenotypes including developmental delay39. This observation
suggests a therapeutic window for FAM50A inhibition. Notably,
although we observed the interaction of FAM50A/FAM50B in all
cell lines screened, many genetic interactions are highly context
dependent and influenced by both the genetics of the cell line and
the growth environment. Thus, further studies will be required to
establish all contexts in which the FAM50A/FAM50B interaction
is operative.
Targeting the FAM50A/FAM50B interaction in vivo. Not all
fitness effects of gene disruption identified in culture can be
replicated in vivo. To assess the possibility of targeting FAM50A
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*Non-significant interactions. Note: Statistical analysis was performed relative to the AIPL1/ACCSL pair.
* * * * * *
Fig. 2 Validation of candidate synthetic lethal pairs. A Schematic of the competitive growth assay. Cas9-expressing cells were infected with lentiviruses
expressing each gRNA in a BFP or mCherry vector to create four populations and read by FACS at day 4 and 14. B Example of a synthetic lethal pair. A375-
Cas9 cells were transduced with lentiviruses expressing CNOT7 (BFP) and CNOT8 (mCherry) sgRNAs and analysed at two timepoints. The growth
phenotype was calculated by measuring the relative depletion of the single-infected and double-infected cells. C Residual values from competitive growth
experiments. Residuals were calculated as the difference between the expected phenotype of the double-positive population (based on summing the
phenotypes of the single positive populations) and the observed phenotype of the double-positive population. Data represent three independent
transductions. The baseline residual for three non-interacting-pairs (negative controls) are also shown (AIPL1&ACCSL, AIPL1&ASF1B, TTC7A/ACCSL).
Residuals were compared with values for the control ACCSL/AIPL1 gene pair. Significance was calculated using a one-way ANOVA and adjusted for
multiple testing using the Dunnett test. All interactions, except where indicated, had a P value < 0.01.
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TOV21G cell line carrying the Dox-inducible FAM50A gRNA
construct mentioned above (see Methods). As shown in Fig. 3C
and 4A, disruption of FAM50A in TOV21G cells precipitated a
profound reduction in cellular fitness. Mice xenografted with the
Dox-inducible line and fed a Dox-containing diet (0.625 g/kg;
ENVIGO) exhibited a significant decrease in tumour growth
compared with controls on a Dox-free diet (Fig. 4B and Source
Data). We noted that after ~30 days, xenografts in which
FAM50A had been disrupted by administration of the Dox diet
appeared to regrow (Fig. 4B). To functionally assess the
mechanisms of resistance, we sequenced the transcriptomes of a
collection of 34 tumours: 17 tumours from Dox-fed mice and 17
control tumours from mice fed normal chow. This analysis
revealed that all tumours that regrew on Dox treatment and were
collected at the ethical endpoint (1.2 cm2) showed CRISPR edit-
ing at the gRNA cut site. These edits included in-frame events,
which presumably were not disruptive of FAM50A but altered the
cut site such that it was no longer a substrate for the gRNA, non-
disruptive missense mutations and null alleles (nonsense and
frameshift mutations). Wildtype traces, representing unedited
alleles, were <1% of sequence reads (Fig. 4C, D). Thus, despite
efficient editing at the gRNA binding site all resistant tumours
were predicted to have retained some FAM50A activity. Collec-
tively, these findings suggest that the genetic interaction between
FAM50A/FAM50B robustly extends to the in vivo setting.
Loss of FAM50A/FAM50B perturbs transcriptional pro-
grammes. FAM50A and FAM50B are proteins with as-yet-
undefined roles. With the exception of N-terminal coiled-coil
domains they lack other recognisable sequence or structural
features40 (Supplementary Fig. 13). FAM50A and FAM50B have
74% DNA and 74.6% amino-acid sequence homology and are
highly conserved throughout evolution. Notably, in Chlamydo-
monas reinhardtii and Schizosaccharomyces pombe orthologues of
these genes have been postulated to be transcription factors or
chromatin regulatory genes40,41, whereas in human cells both
FAM50A and FAM50B have been shown to interact with the C
complex of the spliceosome42,43 and via a high-throughput RNA-
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Fig. 3 The FAM50A/FAM50B axis is a targetable synthetic lethal interaction. A Expression of FAM50B across tumour and normal tissue. Data obtained
from the TCGA36. TPM; transcripts per million. Standard TCGA tumour abbreviations where used. B FAM50B expression inversely correlates with
dependency on FAM50A. These data were derived from the analysis of CRISPR essentiality in 275 cancer lines34. Lines were categorised by their FAM50B
expression using an RPKM cutoff of 1 below which expression was defined as absent. The dependency of FAM50A is shown as scaled log2 fold-change of
FAM50A gRNAs corrected for copy number variation across the cell lines used in this analysis. The p value was calculated with a two-tailed Mann–Whitney
U test. Box-and-whisker plots show 1.5× interquartile ranges and 5–95th percentiles, centres indicate medians. C Analysis of essentiality using isogenic cell
lines. TOV21G-Cas9 and RKO-Cas9, which do not express FAM50B, were transduced with a lentivirus expressing a FAM50B cDNA (F50B+). A375-Cas9
cells express both FAM50A and FAM50B. A FAM50B knockout clone was generated for this cell line (F50B−) using CRISPR. Cells were transduced with a
BFP+ lentivirus carrying a gRNA against FAM50A such that 50% of cells were transduced. Cell proportions were analysed at day 4 and 14. The relative
fold-change of the infected population is shown. p values were obtained using the unpaired two-tailed t test, ****p < 0.0001. Experiments were performed
on three separate occasions in triplicate. Error bars represent the mean and the standard error of the mean (SEM). D Clonogenic confirmation of the
FAM50A/FAM50B genetic interaction. RKO and RKO-F50B+ (complemented with a FAM50B cDNA) were transduced with a lentivirus containing a
doxycycline-inducible gRNA against FAM50A (see Methods). The cells also constitutively expressed Cas9 protein. Cells were seeded at 1000 cells/well;
doxycycline (Dox; 0.1 µg/ml)/DMSO was added at 24 h. Cells were fixed and stained with crystal violet 9 days post seeding. This experiment is
representative of three independent biological replicates.
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In order to assess transcriptomic changes associated with loss
of FAM50A/FAM50B, we transcriptome profiled the effect of
FAM50A knockout on two independent FAM50B null-isogenic
cell line models. Using the TOV21G cell line (constitutively
lacking FAM50B expression) or a CRISPR engineered FAM50B
null A375 clone (A375-F50B−), we introduced a lentiviral vector
carrying a gRNA to disrupt either FAM50A or a non-essential
gene (AIPL1) and cultured the cells for 8 days prior to
transcriptome sequencing. In both cell lines, gene set enrichment
analysis revealed that disruption of FAM50A on a FAM50B null
background resulted in statistically significant (padj < 0.05)
transcriptional changes that included genes of the TP53 and
TNFα/NFκβ pathways, and apoptosis regulators (Supplementary
Fig. 14). As a comparator we also expression profiled FAM50A
(F50A−) and FAM50B (F50B−) knockout A375 cells relative to
parental A375 cells revealing some pathway overlaps (Supple-
mentary Fig. 15).
Cellular phenotypes associated with FAM50A/FAM50B loss.
Following an assessment of RKO cells in culture for phenotypes
associated with FAM50A/FAM50B loss, we noted a marked
increase in micronuclei, a phenotype that was rescued via the
C
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Fig. 4 Effect of FAM50A loss on TOV21G cell growth in vivo and mechanisms of resistance. A Conditional disruption of FAM50A in FAM50B non-
expressing TOV21G cells engineered (see Methods) to contain a dox-inducible FAM50A gRNA. B In vivo consequence of disrupting FAM50A in TOV21G
cells on tumour growth. Data points represent the mean and SEM (see Methods). Dox diet was administered at the day 7 timepoint (arrow). Significance
was defined using a two-tailed Mann–Whitney test by comparing the area under the curve for tumour growth in the Dox-fed and control groups.
*p < 0.0001. These data are representative of two independent experiments. C An example of the FAM50A gRNA cut site showing the profile of editing
events in a doxycycline (Dox)-treated tumour after regrowth. D Editing outcomes at the FAM50A gRNA cut site in tumours collected from untreated (left)
and Dox-fed mice (right). The editing events were annotated using the Variant Effect Predictor (Ensembl). The Y axis is read depth/count.
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introduction of the FAM50B cDNA (F50B+) (Fig. 5A, B, Source
Data). We also observed enhanced micronucleus production in
A375-F50B- cells transduced with a lenti-FAM50A gRNA com-
pared with transduced A375 (wildtype), where loss of FAM50A/
FAM50B also caused an induction of apoptotic cell death
(Fig. 5A–C, and Source Data). Thus, loss of FAM50A/FAM50B
causes widespread alterations in normal cellular gene expression
programmes alongside micronucleation, apoptosis, and cell death.
Discussion
Understanding the genetic wiring of cancer cells provides
opportunities to identify tumour-specific vulnerabilities that
might be exploited clinically. In this study, we screened >1100
gene pairs to identify 27 that were SL in multiple cell lines, several
of which we confirmed with additional validation. Intriguingly, all
nine of the gene pairs identified in all cell lines screened were
paralogues and paralogue pairs were significantly enriched in the
collection of SL interactions we identified. This suggests that,
compared with the other gene sets we analysed, which included
those defined by mutual exclusivity modelling of cancer data,
paralogous genes are of high value for defining synthetic lethal
interactions and candidate therapeutic targets. As there are
multiple agents on the market that inhibit paralogues, such as
trametinib (MEK1, MEK2) and PARP inhibitors (PARP1,
PARP2), each of the 27 gene pairs we identified could be con-
sidered as targets for therapy development if follow-up studies
can identify selectivity for cancer cells. Another way of using
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B
Fig. 5 Disruption of FAM50A/FAM50B results in micronucleus formation and apoptosis. AMicronucleus levels in wildtype (WT), FAM50A null (F50A−)
or FAM50B null (F50B−) A375 cells and WT or FAM50B-complemented (F50B+) RKO cells (left panel). Co-disruption of FAM50A/FAM50B results in a
profound increase in micronucleus levels that can be rescued by FAM50B (F50B+) cDNA complementation (right panel). Cells were collected for analysis
7 days after transduction. The experiment performed on three separate occasions. B Representative images of micronuclei in A375 cell lines from the
experiment in A. Scale bar represents 10 μM. C Analysis of apoptosis at day 7–8 using the CaspGlow assay (see Methods) in A375 cells and isogenic
FAM50A (F50A−) or FAM50B (F50B−) knockout derivative lines. Early apoptosis: CaspGLOW positive/viable. Late apoptosis: CaspGLOW positive/non-
viable. End apoptosis or necrosis: CaspGLOW negative/non-viable. Experiments were performed on three separate occasions in triplicate. For all panels
error bars represent the mean and the standard error of the mean (SEM). p values were calculated using the unpaired two-tailed t test. ****p < 0.0001.
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member of the pair is lost somatically, thus exposing the other
member of the pair as a candidate drug target and the data we
have generated here could be mined for this purpose.
Of note, using TCGA expression data and referencing our
collection of 27 recurrent SL gene pairs, we determined that
FAM50B was silenced in a significant proportion of tumours
across a range of histologies; 0–10% in each tumour type exam-
ined. Further, we showed that co-disruption of FAM50A and
FAM50B both in vitro and in vivo precipitates a profound
reduction in tumour cell fitness, a phenotype that could be par-
tially rescued by reintroduction of FAM50B. Importantly, we
observed dysregulation of a range of cell regulatory transcrip-
tional programmes and the formation of extensive micronuclei
together with apoptotic cell death, suggesting a specific role for
FAM50A/FAM50B in cellular survival via maintenance of genome
stability. In agreement with our study, Dede et al.45 recently
identified FAM50A/FAM50B as a candidate SL gene pair in
cancer cell lines. Our screen is one of the first to profile gene
paralogues as potential drug targets at scale and thus represents a
blueprint for endeavours to prioritise all genes for screening.
Methods
Library construction and lentiviral production. The CRISPR gRNA library was
constructed using the method previously described by Vidigal and Ventura31. A
detailed protocol is available at Protocols.io (dx.doi.org/10.17504/protocols.io.
bpqhmmt6). The gRNAs used are provided in Supplementary Data 2 and 4. In
brief, using the ENSEMBL annotation v79 of the GRCh38 version of the human
reference genome we identified targeting sites in the form of 5′-NNNNNNNNN
NNNNNNNNNNNNGG-3′, which were filtered to remove sequences that were
non-unique and off-target sites using WGE46. Subsequently, using the ENSEMBL
Perl API v84, we identified those gRNAs whose cutting sites were located within a
protein domain as reported by Pfam and then discarded sequences containing BbsI
restriction sites. From the resulting set of gRNAs we selected 3–5 per gene to be
included in the library. Each of these gRNAs were paired with each of the 3–5
gRNAs designed for the other gene in the pair. gRNAs were also individually paired
with a non-targeting Fluc_gRNA control (GTGTTGGGCGCGTTATTTATCGG)
from the Firefly (Photinus pyralis) luciferase gene to allow assessment of single gene
lethality. Single-targeting guides were always under the sU6 promoter (with the
non-targeting gRNA under the hU6 promoter). Combinatorial guides were in a
single orientation (eg hU6 guide_A+ sU6 guide_B). The final library contained
41,838 different combinations of gRNAs including gRNAs targeting a total of 1191
gene pairs, 12,803 gRNAs combined with the Fluc_gRNA control and gRNAs
against essential/non-essential genes to aid in statistical analysis. To make virus,
20 × 106 293 T cells were transfected with 11.25 μg pMD2.G (Addgene #12259), 17
μg psPAX2 (Addgene #12260) and 22.5 μg of dual gRNA library plasmid. Media
was changed 12 h post transduction and virus was harvested 36 h later and stored
at −80 °C.
Cell line culture and screening. All cells were cultured at 37 °C/5%CO2 in media
as specified by ATCC. Cell line identity was confirmed by STR profiling and all
cells were screened and found negative for mycoplasma. Cas9-expressing cell line
generation was performed using a lentivirus produced with the pKLV2EF1a-
Cas9Bsd-W plasmid (Addgene, #68343). The activity was confirmed with a BFP/
GFP reporter assay32. All lines had ≥90% Cas9 activity prior to screening (Sup-
plementary Fig. 2). CD15/CD33 validation experiments in Molm-13 cells (Sup-
plementary Fig. 1) were performed using CD15-APC and CD33-PE antibodies
from Miltenyi (1:5 dilution for both). The combinatorial CRISPR library was
titered using cellular survival in puromycin. Library infections for screening were
performed in triplicate at an MOI of 0.3, at a library representation of 1000×.
Puromycin selection (2 µg/ml for A375, MeWo and 15 µg/ml for RPE-1) was
continued from day 3–7 post transduction. Cells were maintained throughout the
screen at a minimum representation of 3000x. Sequencing was performed on DNA
extracted from these cell cultures at timepoints 14 and 28 days post transduction.
As a control, wildtype A375 cells (Cas9-negative) were transduced with the library
under conditions matching the screening conditions and harvested at day 7.
Sequencing protocol. DNA extraction was performed using a Blood & Cell
Culture DNA Maxi Kit (Qiagen). For each replicate, 48× PCRs containing 3 µg
genomic DNA were performed using KAPA HiFi Polymerase (ThermoFisher),
using the primers listed in Supplementary Data 2. The PCRs were pooled and
cleaned up with a QIAquick PCR purification kit (Qiagen) and SPRI beads
(Beckman). The amplicon was then diluted to 40 pg/µl and a second round PCR
was performed to add indexing primers (Illumina), using 8–10 cycles aiming for a
final concentration of 4 ng/µl. The amplicon was again purified with SPRI select.
The final sequencing was performed to a depth of 500-fold representation/sample,
using a customised two-forward read sequencing strategy with the primers listed in
Supplementary Data 2.
Analysis of the paired library output. We used the Bliss independence model35 to
define synergy between gRNA pairs using the equation:
Expected log2FC g1g2
  ¼ Observed log2FC g1
 þObserved log2FC g2
  ð1Þ
Note, g1g2 represents the paired gRNA construct, targeting two genes, and g1 and
g2 represent each of these guides when paired with a non-targeting (Fluc) control.
In this equation, the synthetic lethality/fitness effect is the difference between the
log2FC of the pair observed in the screen and log2FC expected by the model. We
performed both the control and experimental replicates in triplicate, therefore
comparing each experimental replicate to each control resulted in nine compar-
isons per construct. For each of these nine comparisons, we plotted observed vs
predicted effects, and using Loess regression, the behaviour of the population was
modelled. Population modelling in this way accounts for the effect of CRISPR-
mediated cutting of the genome and the potential effect of single vs double cutting.
For each paired gRNA construct, a residual (vertical distance from the modelled
line) was interpolated. The variance of residuals was found to be heteroscedastic,
with greater variance observed when the expected effect of the guide pair was more
lethal. To correct for this heteroscedasticity, variance smoothing was performed19.
This was done by ranking each g1g2 construct by the expected fold change; the
residuals were then put into bins of 200 (arbitrary number) and the variance of
each bin calculated. The value of each residual was then divided by the variance of
the bin that it belonged to so as to create a variance adjusted residual, resulting in
equal variance across the model. For each gene pair, we then generated up to 225
(25 × 9) independent residuals from each of the gRNA paired constructs.
To derive ‘hits’ from the screen we required significance in two independent
statistical tests; a t test and the robust ranking algorithm (RRA). Gene pairs
typically detected in only the RRA analysis often had a single guide producing a
large residual, with the remaining constructs having minimal biological effect and a
mean effect close to zero. Given that in these cases, the significance of the pair was
often driven by a single guide, possibly driven by off-target effects, we did not wish
to consider these pairs as hits. Gene pairs typically detected in only the t test had a
minor global negative shift, with few guide pairs ranking in the bottom 10% of
residuals. Given that we were interested in pairs which had a large biological effect
(favouring the RRA), but did not want to select genes where a single guide was
causing outliers (favouring the t test) we chose to take the overlap between the two
analyses to ensure size and consistency of effect.
For the t test the equation used was:
t ¼ mean ðVariance adjusted residuals ABÞffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
variance ðVariance adjusted residuals ABÞ
n ðVariance adjusted residuals AB1Þ
q ð2Þ
Robust ranking was performed as detailed previously33 using the bottom 10% of
residual values. For each test (t test or RRA) we used a Bonferroni test to correct for
multiple testing and counted as significant pairs with an FDR < 0.1.
Filtering candidate genetic interactions. We noted that lethal gRNAs defined by
either MAGeCK or BAGEL29,30 analysis of the single gene targeting constructs (i.e.,
gRNAs paired with a non-targeting gRNA), when put under the hU6 promoter in a
gene pair, were more likely to produce a significant residual (p < 2.2 × 10−6, Fisher
exact test). This is likely due to enhanced gRNA activity in this context. In view of
this, we did not consider any pairs containing genes lethal in isolation as screen
hits. Genes were considered lethal if BAGEL or MAGeCK detected them as lethal
in our screen at day 14, or in an independent screen34 (using an FDR < 0.1 for
MAGeCK and a PPV < 5% for BAGEL).
Validation of candidate SL interactions. Genetic interactions were validated
using the technique established previously19. In total, eight pairs underwent low-
throughput validation, with three additional non-interacting pairs used as controls
(AIPL1/ACCSL, AIPL1/ASF1B, TTC7A/ACCSL). Guides showing activity across all
cell lines were chosen for the validation (Supplementary Data 4) and cloned into
the lentiviral pKLV2-U6gRNA5(BbsI)-PGKpuro vector backbone expressing either
BFP or mCherry (Addgene #67974 or #67977). Cells were transduced in triplicate
to create four populations (Fig. 2A) and the abundance of each population was read
at day 4 and day 14 by FACS. Analysis was performed with FlowJo (v10.4.2) and
graphs drawn with GraphPad v7.04 & v8.4.3 and R (3.6.3).
Construction of isogenic cell lines. To generate knockout clones, the A375-Cas9
cell line was transduced with a lentivirus containing a gRNA against FAM50A or
FAM50B at single copy (Supplementary Data 2). Cells were selected with pur-
omycin then single cells sorted by FACS into 96-well plates. Clones were expanded,
and the editing site was Sanger sequenced to confirm editing. Clones chosen for
further studies carried frameshift mutations (Supplementary Fig. 11). The FAM50A
knockout clone was further confirmed by western Blot analysis (Supplementary
Fig. 11) using and anti-FAM50A antibody (ABCAM, Rabbit monoclonal
(ab186410) 1:3000 dilution). An anti-vinculin antibody from Sigma (SAB4200080)
was used as a loading control (1:3000 dilution). An antibody for FAM50B is not
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available. Both FAM50A and FAM50B clones were also validated by visual
inspection of transcriptome sequence data generated as described below.
Two cell lines (RKO-Cas9 and TOV21G-Cas9) lacking FAM50B expression
based on RNAseq data34 were selected for rescue/complementation experiments. A
lentivirus containing a full-length FAM50B cDNA was produced (Myc-DDK
tagged; Origene; RC201531L3) and overexpression of FAM50B confirmed by
western blotting (Myc tag 05-724 [clone 4A6]; Millipore, 1:2000 dilution). To
create inducible knockouts, a gRNA against FAM50A (Supplementary Data 2) was
cloned into the CRISPR pRSGTEBleo-U6Tet-(xx)-EF1-TetRep-2A-Bleo backbone
(Cellecta) following the manufacturer’s instructions and correct assembly
confirmed by Sanger sequencing. This vector was transduced into RKO-Cas9 and
TOV21G-Cas9 cells. Five days after transduction cells were single cell sorted into
96-well plates, and one week post sorting 200 µg/ml zeocin was added to the media
for 3 weeks to identify resistant clones.
Clonogenic assays. Cells were seeded into six-well plates at 1000 cells/well. 24 h
post seeding, media was changed to either contain doxycycline (0.1 µg/ml) or an
equivalent volume of dimethyl sulfoxide (DMSO). The assay was terminated as
cells in the control (DMSO) wells approached confluence. Cells were fixed with
100% ice-cold methanol and stained with 1% crystal violet solution.
Apoptosis assays. The CaspGlow assay (ThermoFisher) was used to assess
apoptosis at day 7/8 after viral transduction as per the manufacturer’s instructions.
RNASeq analysis. To assess the transcriptional effect of co-disruption of FAM50A
and FAM50B, A375 FAM50B cells (A375-F50B−) and TOV21G cells were seeded
at 500,000 cells per well in six-well plates with 8 µg/ml polybrene, and transduced
with either the BFP-F50A_gRNA lentivirus or the BFP-AIPL1_gRNA lentivirus to
infect >90% of cells. Media was changed at 24 h and cells were maintained in
culture until harvest (day 7–8). The experiment was performed as three inde-
pendent transductions per condition. RNA extraction was performed with the
Direct-zol RNA microprep (Zymo research; R2060) according to manufacturers’
instructions. Library preparation was performed using the KAPA stranded RNAseq
kit using RiboErase. Samples were multiplexed and sequenced on a HiSeq 2500
with 75 bp paired-end reads. Sequences were pseudo-aligned to the Homo Sapiens
transcriptome and quantified using the Kallisto quantifier47 (v 0.44.0). We ran
DESeq248 on the gene-level counts, first removing all genes with low-level counts.
Gene set enrichment analysis was performed with fgsea (https://bioconductor.org/
packages/release/bioc/html/fgsea.html).
In vivo assessment of FAM50A essentiality in TOV21G xenografts. For
examination of primary tumour growth, NOD-SCID mice at 6–8 weeks of age were
subcutaneously administered 2.5 × 106 TOV21G- iF50A clone 9 cells (in 0.1 mL
phosphate-buffered saline; PBS) in the right flank. The mice were fed Mouse
Breeders Diet (Laboratory Diets, 5021-3) and one week after dosing were randomly
assigned into two cohorts with one being fed a Doxycycline diet (Dox; 625 mg/kg;
Envigo, TD.01306) and the other remaining on the Mouse Breeders Diet for the
remainder of the study. The developing tumours were measured every second day
until they reached 1.2 cm2 (calculated by: longest length measurement × longest
width measurement), at which point animals were humanely sacrificed and the
mass excised and stored at −80 °C. The care of mice in this study and all
experimental procedures was in accordance with Home Office guidelines
(P6B8058BO). Procedures were further approved by the Animal Welfare Ethical
Review Body (AWERB) of the Welcome Trust Sanger Institute. Housing and
husbandry conditions were exactly as detailed previously49. The experiment was
independently replicated twice. The first cohort were female mice and the second
cohort were male.
Micronucleus assay. To count micronuclei, cells were grown on coverslips, then at
the time of the assay, coverslips were washed once with PBS then fixed with three
parts ethanol/1 part acetic acid for one minute. Coverslips were then washed twice
with PBS before mounting onto microscope slides with Vectashield DAPI
mounting medium (Vector Labs). Micronuclei were counted on a Leica micro-
scope, selecting random fields and counting all nuclei and micronuclei in each field
until >500 nuclei had been counted.
All mouse experiments were performed under Home Office Project Licence
P6B8058BO with ethics board approval.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw sequencing data are available for download from the European Genome-
Phenome Archive: CRISPR data: EGAD00001006648 and RNAseq data:
EGAD00001006649. All other data can be found in the Supplementary Data of this paper
or in the Source Data. Source data are provided with this paper.
Code availability
All of the code used in the paper was from published studies and is cited in the
manuscript. Version numbers are provided in the Reporting Summary.
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